Loading quotes...
Forecast
The analysts' average price target is 15,63⏠(+79,86%). The median is 10,30⏠(+18,53%).
| Buy |
Â
3 |
| Hold |
Â
5 |
| Sell |
Â
0 |
News Go to news feed
iTeos Therapeutics acquired by Concentra and delisted from Nasdaq
iTeos Therapeutics became a wholly owned subsidiary of Concentra Biosciences through a merger and its shares were delisted from the Nasdaq; shareholders received USD 10.047 in cash plus a contingent value right (CVR). All merger conditions were met, about 72.17% of outstanding shares were tendered, the board of directors of iTeos resigned and leadership positions were filled by representatives of Concentra Merger Sub VIII, Inc. Leerink Partners cut its price target for iTeos in light of the takeover; the company intends to terminate its SEC registration. » More on de.investing.com
Financials
| (EUR) | Jun 2025 | |
|---|---|---|
| Revenue | 0,00 | - |
| Gross profit | 0,00 | - |
| Net profit | â66,80M | - |
| EBITDA | â56,15M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 385,30M⏠|
Number of shares | 44,21M |
52-week high/low | 15,14⏠- 4,12⏠|
| Dividends | No |
Beta | 1,49 |
P/E ratio | â3,89 |
PEG ratio | 0,07 |
P/B ratio | 0,90 |
P/S ratio | 0,00 |
Company profile
Iteos Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich mit der Entdeckung und Entwicklung von immunonkologischen Therapeutika fĂŒr Patienten befasst. Die Produktpipeline des Unternehmens umfasst Inupadenant, einen niedermolekularen Antagonisten der Adenosin-A2AR-Antagonisten, der sich in der klinischen Phase 2 befindet, und EOS-448, einen Antagonisten von TIGIT oder T-Zell-Immunrezeptor mit Ig- und ITIM-DomĂ€nen, der sich in der klinischen Phase 1/2 befindet und dazu dient, den Fc-Gamma-Rezeptor oder Fc?R zur Aktivierung von dendritischen Zellen und Makrophagen und zur Förderung der antikörperabhĂ€ngigen zellulĂ€ren ZytotoxizitĂ€t (ADCC-AktivitĂ€t). Iteos Therapeutics, Inc. wurde 2011 gegrĂŒndet und hat seinen Hauptsitz in Watertown, Massachusetts.
| Name | iTeos Therapeutics |
| CEO | Michel Detheux |
| Headquarters | Watertown,
ma USA |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 07/24/2020 |
| Employees | 173 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ITOS |
Discover assets
Shareholders of iTeos Therapeutics also invest in the following assets
